Picture: Apaxen S.A.

Apaxen S.A. appoints CEO

Bart Wuurman joined the young Belgian biotechnology company Apaxen S.A. in November as new CEO.

He has a reputation as an experienced biotech CEO with over 30 years in innovative drug and business development, biotech financing and licensing. As CEO he led De Novo Pharmaceuticals (UK), AM-Pharma and Lanthio Pharma (NL) and Lyramid Ltd. (AUS). Furthermore he is Director of Hercules Pharmaceuticals (NL). He was also Managing Director of the life-science focused venture fund DDF Ventures (NL).

Wuurman succeds Joel Crouzet, who has left the company. Apaxen, situated in Gosselies and founded in 2018, develops novel drug candidates for treatment of chronic inflammatory or autoimmune diseases.